New cocktail of drugs aims to tackle tough pancreatic cancer
NCT ID NCT07302841
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests a combination of four drugs—tunlametinib, two chemotherapies, and a targeted antibody—as a first treatment for people with advanced pancreatic cancer that cannot be removed by surgery. The trial will enroll 28 patients who have not had prior therapy. Researchers will measure how well the tumors shrink and monitor side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Tunlametinib (a targeted drug) combined with gemcitabine, albumin paclitaxel (chemotherapy), and cetuximab β (a monoclonal antibody)
- What this could lead to
- If successful, this combination could offer a new first-line treatment option for advanced pancreatic cancer, potentially improving tumor shrinkage and survival.
- What could go wrong
- This is a small, early-phase trial with only 28 participants and no control group, so results may not be generalizable. The drug combination may cause significant side effects and may not prove effective in larger studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted antibody slow advanced pancreatic cancer?
- AI trained on thousands of pancreatic cancer cases could revolutionize diagnosis
- New device aims to make pancreatic and bile duct procedures safer
- New Antibody-Drug combo takes on Hard-to-Treat pancreatic cancer
- New drug targets Hard-to-Treat pancreatic cancer by hitting a common mutation
- Experimental combo targets Hard-to-Treat pancreatic cancer